Silvia FernÃ;ndez de Mattos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9165593/publications.pdf

Version: 2024-02-01

393982 395343 33 2,396 19 33 citations h-index g-index papers 33 33 33 3758 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cell Cycle Inhibition by FoxO Forkhead Transcription Factors Involves Downregulation of Cyclin D. Molecular and Cellular Biology, 2002, 22, 7842-7852.	1.1	510
2	FoxO3a Transcriptional Regulation of Bim Controls Apoptosis in Paclitaxel-treated Breast Cancer Cell Lines. Journal of Biological Chemistry, 2003, 278, 49795-49805.	1.6	441
3	Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene, 2005, 24, 2317-2329.	2.6	266
4	FoxO3a and BCR-ABL Regulate cyclin D2 Transcription through a STAT5/BCL6-Dependent Mechanism. Molecular and Cellular Biology, 2004, 24, 10058-10071.	1.1	155
5	The Forkhead Transcription Factor FOXO3a Increases Phosphoinositide-3 Kinase/Akt Activity in Drug-Resistant Leukemic Cells through Induction of PIK3CA Expression. Molecular and Cellular Biology, 2008, 28, 5886-5898.	1.1	150
6	H2O2 Induces a Transient Multi-phase Cell Cycle Arrest in Mouse Fibroblasts through Modulating Cyclin D and p21Cip1 Expression. Journal of Biological Chemistry, 2002, 277, 13761-13770.	1.6	142
7	Progestins Regulate the Expression and Activity of the Forkhead Transcription Factor FOXO1 in Differentiating Human Endometrium. Molecular Endocrinology, 2006, 20, 35-44.	3.7	127
8	FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Molecular Cancer Therapeutics, 2008, 7, 3237-3246.	1.9	117
9	EGFR Inhibition in Glioma Cells Modulates Rho Signaling to Inhibit Cell Motility and Invasion and Cooperates with Temozolomide to Reduce Cell Growth. PLoS ONE, 2012, 7, e38770.	1.1	52
10	Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leukemia and Lymphoma, 2007, 48, 2172-2178.	0.6	47
11	Quiescence and functional reprogramming of Epstein-Barr virus (EBV)-specific CD8+ T cells during persistent infection. Blood, 2005, 106, 558-565.	0.6	45
12	The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival. British Journal of Haematology, 2012, 156, 334-345.	1.2	37
13	RhoE Inhibits 4E-BP1 Phosphorylation and eIF4E Function Impairing Cap-dependent Translation. Journal of Biological Chemistry, 2009, 284, 35287-35296.	1.6	29
14	Pro-Oxidant Activity of Amine-Pyridine-Based Iron Complexes Efficiently Kills Cancer and Cancer Stem-Like Cells. PLoS ONE, 2015, 10, e0137800.	1.1	28
15	Hydrogen Peroxide Regulates the Mitochondrial Content of Uncoupling Protein 5 in Colon Cancer Cells. Cellular Physiology and Biochemistry, 2009, 24, 379-390.	1.1	27
16	Cell Uptake and Localization Studies of Squaramide Based Fluorescent Probes. Bioconjugate Chemistry, 2014, 25, 1537-1546.	1.8	27
17	Convergence of Interferon- \hat{I}^3 and Progesterone Signaling Pathways in Human Endometrium: Role of PIASy (Protein Inhibitor of Activated Signal Transducer and Activator of Transcription-y). Molecular Endocrinology, 2004, 18, 1988-1999.	3.7	26
18	Jab1 Co-activation of c-Jun Is Abrogated by the Serine 10-phosphorylated Form of p27Kip1. Journal of Biological Chemistry, 2002, 277, 32413-32416.	1.6	22

#	Article	IF	CITATIONS
19	Molecular biology of mantle cell lymphoma: From profiling studies to new therapeutic strategies. Blood Reviews, 2009, 23, 205-216.	2.8	20
20	Retama monosperma n-hexane extract induces cell cycle arrest and extrinsic pathway-dependent apoptosis in Jurkat cells. BMC Complementary and Alternative Medicine, 2014, 14, 38.	3.7	19
21	Cyclosquaramides as Kinase Inhibitors with Anticancer Activity. ChemMedChem, 2012, 7, 1472-1480.	1.6	18
22	Activation of phosphatidylinositol 3-kinase is required for transcriptional activity of F-type 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: assessment of the role of protein kinase B and p70 S6 kinase. Biochemical Journal, 2000, 349, 59-65.	1.7	14
23	Efficacy of the GemOxâ€R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma. British Journal of Haematology, 2016, 174, 899-910.	1.2	13
24	Activation of phosphatidylinositol 3-kinase is required for transcriptional activity of F-type 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: assessment of the role of protein kinase B and p70 S6 kinase. Biochemical Journal, 2000, 349, 59.	1.7	12
25	An E2F-binding site mediates the activation of the proliferative isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase by phosphatidylinositol 3-kinase. Biochemical Journal, 2002, 368, 283-291.	1.7	11
26	Toward a Rational Design of Polyamine-Based Zinc-Chelating Agents for Cancer Therapies. Journal of Medicinal Chemistry, 2020, 63, 1199-1215.	2.9	9
27	N-(2-methyl-indol-1H-5-yl)-1-naphthalenesulfonamide: A novel reversible antimitotic agent inhibiting cancer cell motility. Biochemical Pharmacology, 2016, 115, 28-42.	2.0	7
28	The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells. Cellular Oncology (Dordrecht), 2019, 42, 521-536.	2.1	7
29	Insulin inhibits glucocorticoid-stimulated L-type 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene expression by activation of the c-Jun N-terminal kinase pathway. Biochemical Journal, 2001, 353, 267.	1.7	5
30	Glioblastoma Embryonic-like Stem Cells Exhibit Immune-Evasive Phenotype. Cancers, 2022, 14, 2070.	1.7	4
31	An intronic AP-1 sequence mediates the transcriptional activation of the F-type 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase by serum. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2002, 1574, 131-136.	2.4	3
32	Increase in Fru-2,6-P2 levels results in altered cell division in Schizosaccharomyces pombe. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 144-152.	1.9	3
33	Therapeutic concepts in mantle cell lymphoma. European Journal of Haematology, 2010, 85, 371-386.	1.1	3